A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy — IMvigor011

Muscle-invasive Bladder Cancer Clinical Trial

Official title:
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Status Recruiting

Clinical Trial Summary

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04660344
Study type	Interventional
Source	Hoffmann-La Roche
Contact	Reference Study ID Number: BO42843 https://forpatients.roche.com
Phone	888-662-6728 (U.S. and Canada)
Email	global.rochegenentechtrials@roche.com
Status	Recruiting
Phase	Phase 3
Start date	May 3, 2021
Completion date	April 1, 2031

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04687254` - Gender-related Characteristics of Bladder Cancer Treatment
Recruiting	`NCT04099589` - Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT03661320` - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer	Phase 3
Active, not recruiting	`NCT02462239` - Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging	N/A
Withdrawn	`NCT03832673` - Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study	Phase 2
Recruiting	`NCT06373055` - Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Recruiting	`NCT06335667` - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer	N/A
Terminated	`NCT03234153` - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin	Phase 2
Recruiting	`NCT05945108` - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting	`NCT06362330` - Multi-parametric MRI in Patients of Bladder Cancer
Completed	`NCT04209114` - A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer	Phase 3
Active, not recruiting	`NCT00808639` - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma	Phase 2